Proregenerative microenvironment triggered by donor mesenchymal stem cells preserves renal function and structure in mice with severe diabetes mellitus

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Ezquer, Fernando ^a   Giraud Billoud, Maximiliano ^a,b   Carpio, Daniel ^c   Cabezas, Fabian ^a,d   Conget, Paulette ^a   Ezquer, Marcelo ^a  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

^b UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

^c UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^d UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; CHOLESTEROL; COLLAGEN TYPE 1; CREATININE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LAMININ 1; LAMININ BETA1; NEPHRIN; SCATTER FACTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DENSITY; CELL INFILTRATION; CELL PROLIFERATION; CELL REGENERATION; CELLS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETOGENESIS; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; GLOMERULAR FILTRATION BARRIER; GLOMERULUS BASEMENT MEMBRANE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY STRUCTURE; KIDNEY TUBULE DISORDER; MACROPHAGE; MALE; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; RENAL PROTECTION; THERAPY EFFECT; UREA NITROGEN BLOOD LEVEL; ANIMAL; C57BL MOUSE; DIABETIC NEPHROPATHIES; EXPERIMENTAL DIABETES MELLITUS; KIDNEY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

ANIMALIA; MUS;

ANIMALS; CELLULAR MICROENVIRONMENT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; KIDNEY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL;

EID: 84934959188     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/164703     Document Type: Article

References (80)

1. A. J. Collins, R. N. Foley, C. Herzog et al. , "US renal data system2012 annual data report, "TheAmerican Journal ofKidney Diseases, vol. 61, no. 1, supplement 1, p. A7, 2013.
2. Y.-M. Sun, Y. Su, J. Li, and L.-F. Wang, "Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy, " Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 359-361, 2013.
3. A. K. H. Lim, "Diabetic nephropathy-complications and treatment, " International Journal of Nephrology and Renovascular Disease, vol. 7, pp. 361-381, 2014.
4. K. E. White, "Research into the glomerular podocyte-is it relevant to diabetic nephropathy" Diabetic Medicine, vol. 23, no. 7, pp. 715-719, 2006.
5. A. A. Elmarakby and J. C. Sullivan, "Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy, " Cardiovascular Therapeutics, vol. 30, no. 1, pp. 49-59, 2012.
6. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, "Oxidative stress as amajor culprit in kidney disease in diabetes, " Diabetes, vol. 57, no. 6, pp. 1446-1454, 2008.
7. S.-I. Yamagishi, S. Maeda, T. Matsui, S. Ueda, K. Fukami, and S. Okuda, "Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes, " Biochimica et Biophysica Acta, vol. 1820, no. 5, pp. 663-671, 2012.
8. F. N. Ziyadeh, "Mediators of diabetic renal disease: the case for TGF-as the major mediator, " Journal of the American Society of Nephrology, vol. 15, supplement 1, pp. S55-S57, 2004.
9. F. Tögel and C. Westenfelder, "Adult bone marrow-derived stem cells for organ regeneration and repair, " Developmental Dynamics, vol. 236, no. 12, pp. 3321-3331, 2007.
10. A. I. Caplan, "The mesengenic process, " Clinics in Plastic Surgery, vol. 21, no. 3, pp. 429-435, 1994.
11. F. Anglani, M. Forino, D. del Prete, E. Tosetto, R. Torregrossa, and A. D'Angelo, "In search of adult renal stem cells, " Journal of Cellular and Molecular Medicine, vol. 8, no. 4, pp. 474-487, 2004.
12. S. Sedrakyan, S. Angelow, R. E. de Filippo, and L. Perin, "Stem cells as a therapeutic approach to chronic kidney diseases, " Current Urology Reports, vol. 13, no. 1, pp. 47-54, 2012.
13. P. Semedo, C. G. Palasio, C. D. Oliveira et al. , "Early modulation of inflammation by mesenchymal stem cell after acute kidney injury, " International Immunopharmacology, vol. 9, no. 6, pp. 677-682, 2009.
14. P. Semedo, M. Correa-Costa, M. A. Cenedeze et al. , "Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model, " Stem Cells, vol. 27, no. 12, pp. 3063-3073, 2009.
15. G. C. Davey, S. B. Patil, A. O'Loughlin, and T. O'Brien, "Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus, " Frontiers in Endocrinology, vol. 5, article 86, 2014.
16. F. E. Ezquer, M. E. Ezquer, D. B. Parrau, D. Carpio, A. J. Yanez, and P. A. Conget, "Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice, " Biology of Blood and Marrow Transplantation, vol. 14, no. 6, pp. 631-640, 2008.
17. R. H. Lee, M. J. Seo, R. L. Reger et al. , "Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17438-17443, 2006.
18. S. Lv, J. Cheng, A. Sun et al. , "Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting oxidative stress, " Diabetes Research and Clinical Practice, vol. 104, no. 1, pp. 143-154, 2014.
19. J. Ouyang, G. Hu, Y. Wen, and X. Zhang, "Preventive effects of syngeneic bone marrow transplantation on diabetic nephropathy in mice, " Transplant Immunology, vol. 22, no. 3-4, pp. 184-190, 2010.
20. H. Zhou, H.-M. Tian, Y. Long et al. , "Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats, " Chinese Medical Journal, vol. 122, no. 21, pp. 2573-2579, 2009.
21. F. Ezquer, M. Ezquer, V. Simon et al. , "Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice, " Biology of Blood andMarrow Transplantation, vol. 15, no. 11, pp. 1354-1365, 2009.
22. M. Katoh, Y. Ohmachi, Y. Kurosawa, H. Yoneda, N. Tanaka, and H. Narita, "Effects of imidapril and captopril on streptozotocininduced diabetic nephropathy in mice, " European Journal of Pharmacology, vol. 398, no. 3, pp. 381-387, 2000.
23. Y.-C. Tay, Y. Wang, L. Kairaitis, G. K. Rangan, C. Zhang, andD. C. H. Harris, "Can murine diabetic nephropathy be separated from superimposed acute renal failure" Kidney International, vol. 68, no. 1, pp. 391-398, 2005.
24. F. Ezquer, M. Ezquer, D. Contador, M. Ricca, V. Simon, and P. Conget, "The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment, " Stem Cells, vol. 30, no. 8, pp. 1664-1674, 2012.
25. M. Ezquer, F. Ezquer, M. Ricca, C. Allers, and P. Conget, "Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome, " Journal of Hepatology, vol. 55, no. 5, pp. 1112-1120, 2011.
26. B. D. Kubiak, S. P. Albert, L. A. Gatto et al. , "Peritoneal negative pressure therapy prevents multiple organ injury in a chronic porcine sepsis and ischemia/reperfusion model, " Shock, vol. 34, no. 5, pp. 525-534, 2010.
27. J. Ma, H. Nishimura, A. Fogo, V. Kon, T. Inagami, and I. Ichikawa, "Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction, " Kidney International, vol. 53, no. 4, pp. 937-944, 1998.
28. D. Sheehan and B. Hrapchak, Theory and Practice of Histotechnology, Battelle Press, Columbus, Ohio, USA, 1980.
29. A. Benigni, C. Zoja, C. Zatelli et al. , "Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy, " Kidney International, vol. 66, no. 5, pp. 1959-1965, 2004.
30. G. H. Tesch, "Macrophages and diabetic nephropathy, " Seminars in Nephrology, vol. 30, no. 3, pp. 290-301, 2010.
31. C. E. Alpers, K. L. Hudkins, A. M. Gown, and R. J. Johnson, "Enhanced expression of 'muscle-specific' actin in glomerulonephritis, " Kidney International, vol. 41, no. 5, pp. 1134-1142, 1992.
32. Y. Utsunomiya, T. Kawamura, A. Abe et al. , "Significance of mesangial expression of-smooth muscle actin in the progression of IgA nephropathy, " American Journal of Kidney Diseases, vol. 34, no. 5, pp. 902-910, 1999.
33. T. J. M. Geleilete, R. S. Costa, M. Dantas, and T. M. Coimbra, "Alpha-smooth muscle actin and proliferating cell nuclear antigen expression in focal segmental glomerulosclerosis: functional and structural parameters of renal disease progression, " Brazilian Journal ofMedical and Biological Research, vol. 34, no. 8, pp. 985-991, 2001.
34. D. H. T. Ijpelaar, A. Schulz, K. Koop et al. , "Glomerular hypertrophy precedes albuminuria and segmental loss of podoplanin in podocytes in Munich-Wistar-Frömter rats, " The American Journal of Physiology-Renal Physiology, vol. 294, no. 4, pp. F758-F767, 2008.
35. M. Notoya, T. Shinosaki, T. Kobayashi, T. Sakai, and H. Kurihara, "Intussusceptive capillary growth is required for glomerular repair in ratThy-1. 1 nephritis, " Kidney International, vol. 63, no. 4, pp. 1365-1373, 2003.
36. A. Salahudeen, V. Poovala, W. Parry et al. , "Cisplatin induces N-acetyl cysteine suppressible F2 isoprostane production and injury in renal tubular epithehal cells, " Journal of the American Society of Nephrology, vol. 9, no. 8, pp. 1448-1455, 1998.
37. D. A. Butterfield andC. M. Lauderback, "Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid-peptide-associated free radical oxidative stress, " Free Radical Biology and Medicine, vol. 32, no. 11, pp. 1050-1060, 2002.
38. H. Zhou, A. Kato, T. Miyaji et al. , "Urinary marker for oxidative stress in kidneys in cisplatin-induced acute renal failure in rats, " Nephrology Dialysis Transplantation, vol. 21, no. 3, pp. 616-623, 2006.
39. R. Mahfouz, R. Sharma, D. Sharma, E. Sabanegh, and A. Agarwal, "Diagnostic value of the total antioxidant capacity (TAC) in human seminal plasma, " Fertility and Sterility, vol. 91, no. 3, pp. 805-811, 2009.
40. T. Shimo, M. Ohshita, J. Katayama et al. , "Significance of intraglomerular expression of-smooth muscle actin, desmin, and PDGF receptor on glomerulosclerosis in the rat remnant kidney model, " Journal of Toxicologic Pathology, vol. 11, no. 4, pp. 229-234, 1998.
41. J. Floege, M. W. Burns, C. E. Alpers et al. , "Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model, " Kidney International, vol. 41, no. 2, pp. 297-309, 1992.
42. Y. Kaneko, K. Nakazawa, M. Higuchi, K. Hora, and H. Shigematsu, "Glomerular expression of-smooth muscle actin reflects disease activity of IgA nephropathy, " Pathology International, vol. 51, no. 11, pp. 833-844, 2001.
43. G. I. Welsh and M. A. Saleem, "Nephrin-signaturemolecule of the glomerular podocyte" Journal of Pathology, vol. 220, no. 3, pp. 328-337, 2010.
44. H. Yuan, E. Takeuchi, andD. J. Salant, "Podocyte slit-diaphragm protein nephrin is linked to the actin cytoskeleton, " The American Journal of Physiology: Renal Physiology, vol. 282, no. 4, pp. F585-F591, 2002.
45. F. Tögel, K. Weiss, Y. Yang, Z. Hu, P. Zhang, andC. Westenfelder, "Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury, " The American Journal of Physiology-Renal Physiology, vol. 292, no. 5, pp. F1626-F1635, 2007.
46. M. H. Little, "Regrow or repair: potential regenerative therapies for the kidney, " Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2390-2401, 2006.
47. A. Valle-Prieto and P. A. Conget, "Human mesenchymal stem cells efficiently manage oxidative stress, " Stem Cells and Development, vol. 19, no. 12, pp. 1885-1893, 2010.
48. J. F. Navarro-González and C. Mora-Fernández, "The role of inflammatory cytokines in diabetic nephropathy, " Journal of the American Society ofNephrology, vol. 19, no. 3, pp. 433-442, 2008.
49. D. Nguyen, F. Ping, W. Mu, P. Hill, R. C. Atkins, and S. J. Chadban, "Macrophage accumulation in human progressive diabetic nephropathy, " Nephrology, vol. 11, no. 3, pp. 226-231, 2006.
50. F. Y. Chow, D. J. Nikolic-Paterson, R. C. Atkins, andG. H. Tesch, "Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis, " Nephrology Dialysis Transplantation, vol. 19, no. 12, pp. 2987-2996, 2004.
51. F. Y. Chow, D. J. Nikolic-Paterson, E. Ozols, R. C. Atkins, B. J. Rollin, and G. H. Tesch, "Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice, " Kidney International, vol. 69, no. 1, pp. 73-80, 2006.
52. H. Akahori, T. Ota, M. Torita, H. Ando, S. Kaneko, and T. Takamura, "Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression, " Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 2, pp. 514-521, 2005.
53. S. Lv, G. Liu, A. Sun et al. , "Mesenchymal stem cells ameliorate diabetic glomerular fibrosis in vivo and in vitro by inhibiting TGF-signalling via secretion of bone morphogenetic protein 7, " Diabetes and Vascular Disease Research, vol. 11, no. 4, pp. 251-261, 2014.
54. M. Danilewicz and M. Wagrowska-Danilewicz, "Morphometric and immunohistochemical insight into focal segmental glomerulosclerosis in obese and non-obese patients, " Nefrologia, vol. 29, no. 1, pp. 35-41, 2009.
55. H. Kawachi, N. Miyauchi, K. Suzuki, D. H. Gi, M. Orikasa, and F. Shimizu, "Role of podocyte slit diaphragm as a filtration barrier, " Nephrology, vol. 11, no. 4, pp. 274-281, 2006.
56. F. N. Ziyadeh and G. Wolf, "Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy, " Current Diabetes Reviews, vol. 4, no. 1, pp. 39-45, 2008.
57. K. Koop, M. Eikmans, M. Wehland et al. , "Selective loss of podoplanin protein expression accompanies proteinuria and precedes alterations in podocyte morphology in a spontaneous proteinuric rat model, "The American Journal of Pathology, vol. 173, no. 2, pp. 315-326, 2008.
58. R. G. Langham, D. J. Kelly, A. J. Cox et al. , "Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition, " Diabetologia, vol. 45, no. 11, pp. 1572-1576, 2002.
59. P. Mundel and J. Reiser, "Proteinuria: an enzymatic disease of the podocyte, " Kidney International, vol. 77, no. 7, pp. 571-580, 2010.
60. J. E. Wiggins, M. Goyal, S. K. Sanden et al. , "Podocyte hypertrophy, 'adaptation' and 'decompensation' associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction, " Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 2953-2966, 2005.
61. D. B. Bhathena, "Glomerular basement membrane length to podocyte ratio in human nephronopenia: implications for focal segmental glomerulosclerosis, " American Journal of Kidney Diseases, vol. 41, no. 6, pp. 1179-1188, 2003.
62. A. B. Fogo, "Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases, " Kidney International. Supplement, vol. 57, no. 75, pp. S15-S21, 2000.
63. Y. H. Kim, M. Goyal, D. Kurnit et al. , "Podocyte depletion and glomerulosclerosis have a direct relationship in the PANtreated rat, " Kidney International, vol. 60, no. 3, pp. 957-968, 2001.
64. M. E. Pagtalunan, P. L. Miller, S. Jumping-Eagle et al. , "Podocyte loss and progressive glomerular injury in type II diabetes, " The Journal of Clinical Investigation, vol. 99, no. 2, pp. 342-348, 1997.
65. D. Li, N. Wang, L. Zhang et al. , "Mesenchymal stemcells protect podocytes fromapoptosis induced by high glucose via secretion of epithelial growth factor, " StemCell Research andTherapy, vol. 4, no. 5, article 103, 2013.
66. E. I. Prodromidi, R. Poulsom, R. Jeffery et al. , "Bone marrowderived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome, " Stem Cells, vol. 24, no. 11, pp. 2448-2455, 2006.
67. Y. Zhang, C. Ye, G. Wang et al. , "Kidney-targeted transplantation of mesenchymal stem cells by ultrasound-targeted microbubble destruction promotes kidney repair in diabetic nephropathy rats, " BioMed Research International, vol. 2013, Article ID 526367, 13 pages, 2013.
68. E. B. Oliveira-Sales, E. Maquigussa, P. Semedoet al. , "Mesenchymal stemcells (MSC)prevented theprogressionof renovascular hypertension, improved renal function and architecture, " PLoS ONE, vol. 8, no. 11, Article ID e78464, 2013.
69. A. I. Caplan and J. E. Dennis, "Mesenchymal stem cells as trophic mediators, " Journal of Cellular Biochemistry, vol. 98, no. 5, pp. 1076-1084, 2006.
70. D. J. Prockop, D. J. Kota, N. Bazhanov, and R. L. Reger, "Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs), " Journal of Cellular andMolecularMedicine, vol. 14, no. 9, pp. 2190-2199, 2010.
71. Y. Wang, H. E. Johnsen, S. Mortensen et al. , "Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention, " Heart, vol. 92, no. 6, pp. 768-774, 2006.
72. C. Lu, W. Ren, X.-M. Su, J.-Q. Chen, S.-H. Wu, and G.-P. Zhou, "EGF-recruited JunD/c-fos complexes activate CD2AP gene promoter and suppress apoptosis in renal tubular epithelial cells, " Gene, vol. 433, no. 1-2, pp. 56-64, 2009.
73. S. Villanueva, C. Cespedes, A. Gonzalez, and C. P. Vio, "bFGF induces an earlier expression of nephrogenic proteins after ischemic acute renal failure, " The American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 291, no. 6, pp. R1677-R1687, 2006.
74. S. Villanueva, C. Cespedes, A. A. Gonzalez, E. Roessler, and C. P. Vio, "Inhibition of bFGF-receptor type 2 increases kidney damage and suppresses nephrogenic protein expression after ischemic acute renal failure, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 294, no. 3, pp. R819-R828, 2008.
75. W. A. Silva Jr. , D. T. Covas, R. A. Panepucci et al. , "The profile of gene expression of human marrow mesenchymal stem cells, " Stem Cells, vol. 21, no. 6, pp. 661-669, 2003.
76. Y. Zhang, B. Chen, X.-H. Hou et al. , "Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats, " Chinese Medical Journal, vol. 120, no. 11, pp. 988-995, 2007.
77. S. Villanueva, E. Ewertz, F. Carrión et al. , "Mesenchymal stem cell injection ameliorates chronic renal failure in a rat model, " Clinical Science, vol. 121, no. 11, pp. 489-499, 2011.
78. W. Li, Q. Zhang, M. Wang et al. , "Macrophages are involved in the protective role of human umbilical cord-derived stromal cells in renal ischemia-reperfusion injury, " Stem Cell Research, vol. 10, no. 3, pp. 405-416, 2013.
79. F. Djouad, L.-M. Charbonnier, C. Bouffi et al. , "Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependentmechanism, " StemCells, vol. 25, no. 8, pp. 2025-2032, 2007.
80. M. E. Ezquer, F. E. Ezquer, M. L. Arango-Rodŕguez, and P. A. Conget, "MSCtransplantation: a promising therapeutic strategy to manage the onset and progression of diabetic nephropathy, " Biological Research, vol. 45, no. 3, pp. 289-296, 2012.